ICON experts frequently author or contribute to industry trade press. The following are some recent articles.
Diversity and inclusion in clinical trials
Nuala Murphy, President of Clinical Research Services, discusses the need for diversity and inclusion in clinical trials.
Trailblazing women stress importance of diversity in pharma
Nuala Murphy, President of Clinical Research Services at ICON, discusses how increasing diversity is a key area of focus for ICON, both in terms of patient diversity and diversity in the organisation.
Has the pandemic enabled us to accelerate the pace of drug development?
Nuala Murphy, President Global Specialty Solutions, contributes to this Marvellous Medicine BBC4 podcast about accelerating the pace of drug development due to the pandemic.
The central role of Interactive Response Technology in today's clinical trials
Michelle Lynskey, Global Head of Interactive Response Technology and Clinical Supplies Management, offers her insights on the role of IRT in clinical trials.
A trusted partner for clinical development
ICON CEO Steve Cutler chats with Newsweek, on ICON’s role in the development of much needed medicines. The interview (page 12 of PDF) is part of a special report on Ireland.
The pursuit of patient diversity in clinical trials
Nuala Murphy, President of Clinical Research Services, provides expert commentary on the importance of patient diversity in clinical trials.
The tangled web of large outsourced providers
ICON’s $12 billion acquisition of PRA Health Sciences is discussed as part of the changing CRO landscape.
Good CROs make dream teams, great CROs make dynasties
Dr. Nuala Murphy, President of Clinical Research Services, provides expert commentary on the importance of partnerships between CROs and sponsors.
ICON acquisition confirms its status as a global powerhouse in clinical research
An interview in which CEO Dr. Steve Cutler provides an overview of ICON’s evolution and drivers over the past few years from the pandemic to the recent PRA Health acquisition.
The new cancer treatment frontier: Why clinical trials need to keep pace with innovations in cancer research
Andreas Dreps and Martin Lachs discuss the recent advances in cancer research and why oncology clinical trials must make use of these developments to stay ahead of the curve.